Nicardipine Hydrochloride Capsule
NDC Package 24658-751-90

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Nicardipine Hydrochloride capsules are contraindicated in patients with hypersensitivity to the drug. This formulation utilizes a capsule delivery system. Marketed by Puracap Laboratories Llc Dba Blu Pharmaceuticals, this product is identified by NDC 24658-751 and is authorized under FDA application ANDA074928.

Identification & Billing

NDC Package Code
24658-751-90
Package Description
90 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
24658075190
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
90 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Nicardipine Hydrochloride
Non-Proprietary Name
Nicardipine Hydrochloride
Substance Name
Nicardipine Hydrochloride
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Nicardipine hydrochloride capsules are contraindicated in patients with hypersensitivity to the drug. Because part of the effect of nicardipine hydrochloride capsules are secondary to reduced afterload, the drug is also contraindicated in patients with advanced aortic stenosis. Reduction of diastolic pressure in these patients may worsen rather than improve myocardial oxygen balance.

Regulatory & Marketing

Labeler Name
Puracap Laboratories Llc Dba Blu Pharmaceuticals
Product Type
Human Prescription Drug
FDA Application #
ANDA074928
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-15-2016
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 24658-751-90 identifies a specific commercial package of 90 capsule in 1 bottle of Nicardipine Hydrochloride, a human prescription drug labeled by Puracap Laboratories Llc Dba Blu Pharmaceuticals. This capsule is formulated for oral use and contains nicardipine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Puracap Laboratories Llc Dba Blu Pharmaceuticals on December 15, 2016. The current certification is valid through December 31, 2026.

How is this Puracap Laboratories Llc Dba Blu Pharmaceuticals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 24658075190. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
24658-751-90
11-Digit CMS (5-4-2)
24658-0751-90

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.